PRP vs PRF in Aesthetics: Preparation, Clinical Uses, and Evidence

PRP is prepared by centrifuging whole blood at lower speeds (typically 1,200–1,500 rpm for 5–10 minutes) to separate plasma rich in platelets from red blood cells and white blood cells. The result is a liquid suspension of platelets in plasma, usually at a concentration of 3–5× baseline platelet count. Most PRP protocols require the addition of an activator—calcium chloride, thrombin, or silica—to trigger platelet degranulation and release of growth factors (PDGF, VEGF, FGF, TGF-β, IGF-1).

PRF is prepared by centrifuging whole blood at higher speeds (typically 2,400–2,700 rpm for 12–14 minutes) without anticoagulant. This causes the blood to clot during centrifugation, producing a fibrin clot that traps platelets, leukocytes, and fibrinogen. The result is a solid or semi-solid matrix—not a liquid. No external activator is needed; the fibrin scaffold itself is the bioactive structure.

Clinical Behavior and Longevity

The structural difference drives clinical behavior. PRP's liquid form allows rapid diffusion and quick growth-factor release—typically 80% of growth factors are released within the first 24 hours. This makes PRP suitable for immediate, localized effects but means the therapeutic window is narrow.

PRF's fibrin matrix acts as a slow-release depot. Growth factors and cytokines are released over 7–14 days or longer, creating sustained stimulation of fibroblasts and angiogenesis. The fibrin scaffold also provides structural support and may promote cell migration and tissue remodeling more effectively than liquid PRP.

Clinical Uses in Aesthetics

Hair Loss (Androgenetic Alopecia)

Both PRP and PRF are used off-label for male and female pattern hair loss, typically injected into the scalp at the dermal-subcutaneous junction. The evidence for PRP is more robust: multiple RCTs show modest but measurable improvements in hair count, thickness, and growth-phase percentage when administered in series (4–6 sessions, monthly intervals). Improvement typically becomes visible at 3–4 months.

PRF for hair loss has less clinical evidence. Small studies suggest comparable or superior outcomes to PRP, likely due to the sustained growth-factor release and leukocyte content (which may enhance immune tolerance and reduce inflammation). However, the evidence base remains smaller, and PRF protocols vary widely across practices.

Under-Eye Rejuvenation

PRP is commonly injected or microneedled into the periorbital area to address tear-trough hollowing, fine lines, and skin laxity. The rapid growth-factor release stimulates collagen remodeling and angiogenesis. Results are typically subtle—modest improvement in skin quality and fine lines—and appear over 4–8 weeks.

PRF is increasingly used in the under-eye zone, sometimes combined with microneedling. The theory is that the fibrin matrix and sustained cytokine release provide better structural support and longer-lasting collagen stimulation. Clinical reports are favorable, but RCT evidence is limited. Some practitioners prefer PRF for under-eye work because the semi-solid form is easier to control and less likely to diffuse into the orbital septum.

Evidence Quality

PRP for aesthetics has the strongest evidence base. Multiple RCTs support its use in androgenetic alopecia and periorbital rejuvenation, with effect sizes ranging from modest to moderate. Meta-analyses confirm efficacy above placebo, though absolute gains are often 15–25% improvement in measured parameters.

PRF evidence is growing but remains preliminary. Most published data are small case series or uncontrolled observational studies. The lack of standardized PRF protocols (centrifuge speed, tube type, activation method vary) makes cross-study comparison difficult. Mechanistic studies suggest PRF may outperform PRP in sustained growth-factor delivery and immune modulation, but clinical superiority has not been definitively established in head-to-head trials.

Practical Considerations for Practices

Cost and Workflow

PRP requires a centrifuge and activator; cost per treatment is typically $300–600 in materials and labor. PRF requires only a centrifuge and specific PRF tubes; cost is similar or slightly lower. Both are point-of-care, same-day procedures.

Regulatory Status

Neither PRP nor PRF is FDA-cleared as a drug or biologic. Both are autologous preparations and fall under the 361 HCT/P (Human Cells, Tissues, and Cellular and Tissue-Based Products) exemption if prepared in a compliant facility and used for homologous purposes. Off-label use (hair loss, under-eye) is permitted but requires informed consent and documentation of the off-label status.

Patient Messaging

PRP has stronger clinical evidence and more published outcomes data—a legitimate advantage in patient education. PRF's sustained-release mechanism is theoretically compelling but should not be oversold without acknowledging the smaller evidence base. Both require multiple sessions and realistic timelines (3–4 months for visible results).

Practices considering either modality should verify their centrifuge meets 361 HCT/P compliance standards, document informed consent for off-label uses, and track outcomes systematically to build internal evidence.